Advertisement
U.S. markets open in 3 hours 56 minutes

Molecular Templates, Inc. (MTEM)

NasdaqCM - NasdaqCM Delayed Price. Currency in USD
2.0700-0.6800 (-24.73%)
At close: 04:00PM EDT
2.0900 +0.02 (+0.97%)
After hours: 07:39PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Double Moving Average Crossover

Double Moving Average Crossover

Previous Close2.7500
Open2.7500
Bid2.9700 x 800
Ask3.2200 x 800
Day's Range2.0000 - 2.7600
52 Week Range2.0000 - 9.4500
Volume71,812
Avg. Volume11,055
Market Cap11.125M
Beta (5Y Monthly)1.20
PE Ratio (TTM)N/A
EPS (TTM)-6.9200
Earnings DateMar 28, 2024 - Apr 01, 2024
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est16.50
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for MTEM

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Molecular Templates, Inc.
    Analyst Report: Johnson & JohnsonJohnson & Johnson is the world's largest and most diverse healthcare firm. Three divisions make up the firm: pharmaceutical, medical devices and diagnostics, and consumer. The drug and device groups represent close to 80% of sales and drive the majority of cash flows for the firm. The drug division focuses on the following therapeutic areas: immunology, oncology, neurology, pulmonary, cardiology, and metabolic diseases. The device segment focuses on orthopedics, surgery tools, vision care, and a few smaller areas. The last segment of consumer focuses on baby care, beauty, oral care, over-the-counter drugs, and women’s health. Geographically, just over half of total revenue is generated in the United States.
    Rating
    Fair Value
    Economic Moat
    3 years agoMorningstar
View more
  • GlobeNewswire

    Molecular Templates, Inc. Provides Interim Update

    Monotherapy activity with PD-L1-targeting MT-6402 in Head and Neck Cancer; Unique pharmacodynamic effects with CTLA-4 targeting MT-8421 in on-going phase I study Monotherapy Activity with MT-6402 in Low-PD-L1 Relapsed/Refractory SCHNN Patients (N=8) Monotherapy Activity with MT-6402 in Low-PD-L1 Relapsed/Refractory SCHNN Patients (N=8) MT-8421 Induces Unique Pharmacodynamic Effects MT-8421 Induces Unique Pharmacodynamic Effects AUSTIN, Texas, March 04, 2024 (GLOBE NEWSWIRE) -- Molecular Template

  • GlobeNewswire

    Molecular Templates to Present at Oppenheimer 34th Annual Healthcare Life Sciences Conference

    AUSTIN, Texas, Feb. 08, 2024 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” or “MTEM”), a clinical-stage biopharmaceutical company developing novel therapeutics with potent and differentiated mechanisms of action for cancer, announced participation in the upcoming Oppenheimer 34th Annual Healthcare Life Sciences Conference. Oppenheimer 34rd Annual Healthcare Conference, February 13 – 14 Format: Virtual PresentationDate: Wednesday, February 14, 2024Time: 9:20

  • GlobeNewswire

    Molecular Templates, Inc. Reports Third Quarter 2023 Financial Results and Business Update

    MT-6402 Dose Escalation (Part A) Head & Neck Patients (N=8) AUSTIN, Texas, Nov. 13, 2023 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” or “MTEM”), a clinical-stage biopharmaceutical company focused on the discovery and development of proprietary targeted biologic therapeutics, engineered toxin bodies (“ETBs”), to create novel therapies with potent differentiated mechanisms of action for cancer, today reported financial results and business updates for the th